Boothbay Fund Management’s NRX Pharmaceuticals NRXP Stock Holding History

Boothbay Fund Management’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-10,000	Closed	-$1.06M	–	944
2019 Q3	$1.06M	Sell	10,000 -20,000	-67%	-$2.09M	0.1%	293
2019 Q2	$3.14M	Hold	30,000	–	–	0.29%	77
2019 Q1	$3.11M	Hold	30,000	–	–	0.3%	72
2018 Q4	$3.06M	Hold	30,000	–	–	0.45%	44
2018 Q3	$3.01M	Hold	30,000	–	–	0.3%	71
2018 Q2	$2.97M	Sell	30,000 -23,953	-44%	-$2.36M	0.26%	75
2018 Q1	$5.3M	Buy	+53,953	New	+$5.26M	0.63%	34

Other funds holding NRXP

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

VOAM

Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return

Boothbay Fund Management's NRXP Position: Q4 2019 in Review

Boothbay Fund Management sold out of NRX Pharmaceuticals (NRXP) in Q4 2019, closing a stake of 10,000 shares — an estimated $1.06M sold.

Boothbay Fund Management first reported a position in NRXP in Q1 2018 and held it in 7 quarters. The position peaked at $5.3M in Q1 2018. 13 funds tracked by Wall St. Rank hold NRXP as of Q4 2019.

Boothbay Fund Management reported no remaining NRX Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Boothbay Fund Management sold 10,000 NRX Pharmaceuticals shares in Q4 2019, an estimated $1.06M.
Boothbay Fund Management first reported a position in NRX Pharmaceuticals in Q1 2018 and held it in 7 quarters.
Boothbay Fund Management's NRX Pharmaceuticals position peaked at $5.3M in Q1 2018.
13 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q4 2019.

Based on Boothbay Fund Management's 13F filing for Q4 2019, filed 14 Feb 2020.